![M&A and Strategic Deals: Thermo Fisher, BD, and Quest Use M&A to Advance Post-COVID-19 Strategies](https://www.g2intelligence.com/wp-content/uploads/2023/07/August23.LIR_.MandA-iStock-1404269031_1100x800-1080x675.jpg)
M&A and Strategic Deals: Thermo Fisher, BD, and Quest Use M&A to Advance Post-COVID-19 Strategies
Diagnostics companies that invested heavily in COVID-19 products are relying on M&A transactions to restructure and transition.
Diagnostics companies that invested heavily in COVID-19 products are relying on M&A transactions to restructure and transition.
After an eventful month in the Illumina-GRAIL saga, the story may soon be over.
After a significant lull, M&As in the lab diagnostics space heated up in May, with several key deals announced.
The biggest story in M&A dealmaking continues to be the deal that’s being undone—Illumina’s acquisition of GRAIL.
Carl Icahn has decided to take his beef with Illumina’s board of directors over the acquisition directly to company shareholders.